Involvement of cytochrome P450 enzymes in inflammation and cancer: a review

Area of Science:

• Biochemistry
• Pharmacology
• Oncology

Background:

• Cytochrome P450 (CYP) enzymes are critical for drug and xenobiotic metabolism.
• Proinflammatory cytokines (e.g., IL-1, IL-6, TNF-α, IFN-γ) can inhibit or induce CYP enzyme activity.
• These cytokines and altered CYP activity are implicated in cancer development and progression.

Purpose of the Study:

• To review the role of CYPs in major cancers like hepatocarcinoma, breast, and lung cancer.
• To examine the impact of inflammation-mediated CYP modulation on chemotherapy outcomes.
• To highlight the importance of understanding the inflammation-CYP-cancer axis for drug interactions and therapeutic efficacy.

Main Methods:

• Comprehensive review of in vitro, in vivo, and clinical studies.
• Analysis of the interplay between proinflammatory cytokines and CYP enzymes in the tumor microenvironment.
• Examination of CYP polymorphisms and their influence on enzyme activity.

Main Results:

• Inflammation-driven CYP modulation can promote carcinogenesis.
• Altered CYP activity affects chemotherapy efficacy, leading to toxicity or treatment failure.
• CYP polymorphisms contribute to variations in drug response and cancer susceptibility.

Conclusions:

• Elucidating the relationship between inflammation, CYPs, and cancer is essential for personalized medicine.
• Targeting inflammation or CYP pathways may offer novel therapeutic strategies.
• Predicting drug interactions and optimizing chemotherapy require consideration of the tumor microenvironment's inflammatory state.